Thursday, August 13, 2020 10:34:58 PM
Please say this is not all we have. Its nice we have a "web site person".
We need a pr company - with contacts everywhere, people that can make a call, and get the CEO or expert on national TV.
This is the end game now. You need people talking about your company everywhere. You need people asking at their doctor, their hospital - can I join the M/M trial for LL? Can I get it? You need it to be the talk of peoples zoom's with other team mates at work.
The WSJ article was a master stroke - it didn't attack the company directly - it called into question every retail investors sanity and maybe even a few pro's. It was from the WSJ.
Website - its okay, does the job (but spelling mistakes? I expect that from me, not a pro), but I don't even know if the website is registered to be picked up in google. Google search say "covid treatments" - cytodyn doesn't appear. Get some search engine optimization going people. Even if you refine the time to say to TODAY - all you get is stat news and WSJ articles and bad articles. I can't find any major news site talking about it. What is our Adsense budget ?
Please no more PA interviews - they are not working anymore.
We have the only company with a treatment proven in a double blinded test under FDA guidelines that significantly reduces the odds of a patient going to ICU with no side effects. Removes the complications in 3 days. Treatment can be administered at home.
And no-one knows about it.
Thats why the shorts are destroying investor value.
NP - here is a tip - don't be surprised you loose your company to BP. You have a lot of shares issued - use that as your defense - get people interested now, get the SP up by raising awareness and you will have a chance of keeping this amazing molecule alive.
Get a top dollar PR firm. Now. Don't be penny wise and pound foolish. Get a CMO and a few staff full time - tell them they have one week to get all the links you have to journals, etc together. Make it easy for people at any level to join the dots. Remove any doubt for people, without them having to google for days.
Get that team talking to more hospitals, drum up support, interest. Get a phase 3 started anyway. Get more hospitals. Move quickly - BP is after you and your unmeet need is about to be meet. By something else.
Get people on your team that have connections in the FDA, have worked there. Can pick up the phone and talk to people. Setup up presentation etc.
$ - I hope the company has been selling at $4 ish - sell 5M shares that will buy a lot of PR and will easily pay for itself.
So frustrating seeing nothing about this amazing result. I am not saying this only because of the upside to this stock. I am frustrated as I just want the world to return to normal. I want coffee shops to open. I want to go on a vacation. I want the economy to start working again. Thats really more important - the money will take care of itself then.
We need a pr company - with contacts everywhere, people that can make a call, and get the CEO or expert on national TV.
This is the end game now. You need people talking about your company everywhere. You need people asking at their doctor, their hospital - can I join the M/M trial for LL? Can I get it? You need it to be the talk of peoples zoom's with other team mates at work.
The WSJ article was a master stroke - it didn't attack the company directly - it called into question every retail investors sanity and maybe even a few pro's. It was from the WSJ.
Website - its okay, does the job (but spelling mistakes? I expect that from me, not a pro), but I don't even know if the website is registered to be picked up in google. Google search say "covid treatments" - cytodyn doesn't appear. Get some search engine optimization going people. Even if you refine the time to say to TODAY - all you get is stat news and WSJ articles and bad articles. I can't find any major news site talking about it. What is our Adsense budget ?
Please no more PA interviews - they are not working anymore.
We have the only company with a treatment proven in a double blinded test under FDA guidelines that significantly reduces the odds of a patient going to ICU with no side effects. Removes the complications in 3 days. Treatment can be administered at home.
And no-one knows about it.
Thats why the shorts are destroying investor value.
NP - here is a tip - don't be surprised you loose your company to BP. You have a lot of shares issued - use that as your defense - get people interested now, get the SP up by raising awareness and you will have a chance of keeping this amazing molecule alive.
Get a top dollar PR firm. Now. Don't be penny wise and pound foolish. Get a CMO and a few staff full time - tell them they have one week to get all the links you have to journals, etc together. Make it easy for people at any level to join the dots. Remove any doubt for people, without them having to google for days.
Get that team talking to more hospitals, drum up support, interest. Get a phase 3 started anyway. Get more hospitals. Move quickly - BP is after you and your unmeet need is about to be meet. By something else.
Get people on your team that have connections in the FDA, have worked there. Can pick up the phone and talk to people. Setup up presentation etc.
$ - I hope the company has been selling at $4 ish - sell 5M shares that will buy a lot of PR and will easily pay for itself.
So frustrating seeing nothing about this amazing result. I am not saying this only because of the upside to this stock. I am frustrated as I just want the world to return to normal. I want coffee shops to open. I want to go on a vacation. I want the economy to start working again. Thats really more important - the money will take care of itself then.
Recent CYDY News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
